Sotorasib

Sotorasib
Sonraí cliniciúla
Grúpa cógaseolaíochta	comhdhúil cheimiceach
Sonraí ceimiceacha agus fisiceacha
Foirmle	C30H30F2N6O3
Mais mhóilíneach	560.23474526 Da
Uimhir CAS	2296729-00-3
PubChem (SID)	137278711
IUPHAR/BPS	10678
DrugBank	15569
ChemSpider	72380148
UNII	2B2VM6UC8G
ChEBI	178199

Is cógas frith-ailse é Sotorasib, a dhíoltar faoi na hainmneacha branda Lumakras agus Lumykras, agus a úsáidtear chun ailse neamh-bheagcheallach na scamhóg (ANBCS) a chóireáil.^[1] Díríonn sé ar shóchán ar leith, G12C, sa phróitéin KRAS atá freagrach as cineálacha éagsúla ailse.^[2]^[3]

I measc na fo-iarsmaí is coitianta tá buinneach, pian mhatánchnámharlaigh, masmas, tuirse, damáiste ae agus casacht.^[4]

Tá Sotorasib ina choscóir ar an theaghlach RAS GTPase.^[5] Is ionann sócháin KRAS G12C agus thart ar 13% de na sócháin in ailsí scamhóg cille neamh-bheag.

Ceadaíodh Sotorasib le haghaidh úsáide míochaine sna Stáit Aontaithe i mBealtaine 2021.^[6]^[7]

Tagairtí[cuir in eagar | athraigh foinse]

↑ https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug%7Cwork=U.S. Food and Drug Administration}
↑ NCI Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/794411%7Cwork=}}
↑ The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.Nature,volume 575, issue=7781,pages 217–23
↑ U.S. Food and Drug Administration (FDA). https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug."FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy".
↑ Earráid leis an lua: Invalid <ref> tag; no text was provided for refs named FDA PR 20210528
↑ U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug"FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy".
↑ https://www.cnbc.com/2021/05/28/fda-approves-amgen-drug-for-lung-cancer-with-specific-mutation-.html%7Cwork=CNBC}}^{[nasc briste go buan]}

[1] ttps://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug%7Cwork=U.S. Food and Drug Administration}

[2] NCI Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/794411%7Cwork=}}

[3] The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.Nature,volume 575, issue=7781,pages 217–23

[4] U.S. Food and Drug Administration (FDA). https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug."FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy".

[FDA_PR_20210528-5] Earráid leis an lua: Invalid <ref> tag; no text was provided for refs named FDA PR 20210528

[6] U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug"FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy".

[7] ttps://www.cnbc.com/2021/05/28/fda-approves-amgen-drug-for-lung-cancer-with-specific-mutation-.html%7Cwork=CNBC}}^{[nasc briste go buan]}

[1]

[2]

[3]

[4]

[5]

[6]

[7]